OncoMatch/Clinical Trials/NCT05902988
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Is NCT05902988 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies VLS-1488 for advanced solid tumor.
Treatment: VLS-1488 — This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Excluded: MSH2 deficient mismatch repair
dMMR
Excluded: POLE hotspot mutated
POLE gene hotspot mutated
Disease stage
Metastatic disease required
at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: kif18a inhibitor
Lab requirements
Cardiac function
mi or stroke ≤ 1 year, unstable angina/pe/dvt/cabg ≤ 6 months, nyha class ≥ ii, lvef < 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Southern California · Los Angeles, California
- Hoag Memorial Hospital · Newport Beach, California
- University of Colorado Cancer Center · Aurora, Colorado
- Yale Cancer Center · New Haven, Connecticut
- Kellogg Cancer Center · Evanston, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify